Description du projet
Optimisation du traitement antithrombotique chez les patients atteints de cancer en fin de vie
Le traitement antithrombotique (TTA) a des effets positifs négligeables sur le bien-être des patients atteints de cancer en phase terminale. Le TTA est cependant souvent poursuivi jusqu’au décès du patient, ce qui provoque des hémorragies et accroît la charge de morbidité ainsi que le coût des soins de santé. Le projet SERENITY, financé par l’UE, vise à mettre au point un outil d’aide à la prise de décision partagée (OAPDP), fondé sur le web et axé sur l’information, afin de faciliter la stratégie concernant l’utilisation du TTA chez les patients atteints de cancer en fin de vie. L’approche globale adoptée par le projet combinera des examens, des recherches «flash mob», des études épidémiologiques européennes et des entretiens qualitatifs. Les résultats seront utilisés dans le cadre d’un processus Delphi afin de parvenir à un consensus sur la conception optimale de l’OAPDP, qui se veut spécifique au patient et adaptée aux facteurs socio-économiques et liés à la maladie.
Objectif
Despite the fact that antithrombotic therapy (ATT) has little or even negative effects on the well-being of cancer patients during their last year of life, stopping ATT is rare in clinical practice. In contrast, ATT is often continued until death, resulting in excess bleeding, higher healthcare costs, and increased disease burden. SERENITY will develop an information-driven, palliative care shared decision-making process enabled by a user-friendly, easily accessible, web-based shared decision support tool (SDST) that will facilitate treatment decisions regarding appropriate use of ATT in cancer patients at the end of life. SERENITY will use a comprehensive approach consisting of a combination of realist review, flash mob research, three epidemiologic studies in NL, UK, and DK, and qualitative interviews. The results of these studies will be used in a Delphi process to reach consensus on the optimal design of the intervention. Using the consensus reached in the Delphi process, the SDST will be designed to be patient-specific with adaption to gender, cancer-related, cultural, and socioeconomic factors. Proceeding, the SDST will be tested and optimised in a Randomised Clinical Trial. A targeted implementation and exploitation plan will be developed to enable the use of the SERENITY approach across Europe, as well as incorporation in national and pan-European clinical guidelines and policies. The intervention will ultimately lead to appropriate use of ATT, prevention of bleeding complications, and considerable cost savings in addition to improved quality of life and treatment satisfaction of patients, their carers, and involved healthcare professionals. The intervention will empower cancer patients and their carers, enabling them to make their own choices. The intervention will reduce the disease burden of hundreds of thousands of people living with cancer receiving palliative care each year, throughout all EU regions.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
2333 ZA Leiden
Pays-Bas